BREAKING! First-in-the-World Ivermectin, Mebendazole, and Fenbendazole Protocol in Cancer Has Been Peer-Reviewed and Published September 19/2024!
Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol
Dr. Makis proudly announces that this groundbreaking paper is the first peer-reviewed and published work to propose a cancer treatment protocol leveraging the remarkable properties of ivermectin, mebendazole, and fenbendazole. This research represents a significant labor of love.
Special thanks go to the lead authors, Ilyes Baghli and Pierrick Martinez, for their incredible and inspired contributions, as well as to Dr. Paul Marik from FLCCC for his extensive work on repurposed drugs. Gratitude is also extended to every co-author who dedicated their efforts to bring this paper to fruition.
Dr. Makis hopes that this paper will pave the way for a revolutionary future in cancer treatment.
In recent years, the mitochondrial-stem cell connection (MSCC) theory has gained attention in cancer research. This theory suggests that cancer originates from chronic oxidative phosphorylation (OxPhos) insufficiency in stem cells, leading to the formation of cancer stem cells (CSCs) and abnormal energy metabolism.
A hybrid orthomolecular protocol has been proposed to target the MSCC in cancer treatment. This protocol includes a combination of orthomolecules, drugs, and dietary changes aimed at enhancing OxPhos, inhibiting the primary fuels of cancer cells (glucose and glutamine), and targeting CSCs and metastasis.
The study, published in the Journal of Orthomolecular Medicine in September 2024, underwent a rigorous peer review process. The authors, including Ilyes Baghli, William Makis, Paul E. Marik, and others, drew on insights from molecular biology, pharmacology, and clinical studies to develop this protocol.
Key Components of the Protocol
1. Ivermectin: Known for its antiparasitic properties, ivermectin has shown potential in modulating cancer pathways and supporting the body's natural healing mechanisms.
2. Mebendazole: This antiparasitic drug has been found to inhibit cancer cell growth and promote apoptosis.
3. Fenbendazole: Another antiparasitic drug, fenbendazole, has demonstrated anti-cancer activity by disrupting cancer cell metabolism.
4. Metformin: Known for its glucose-lowering effects, metformin also inhibits mitochondrial complex I, reducing cancer cell proliferation.
5. Dichloroacetate (DCA): This drug shifts cancer cell metabolism from glycolysis to oxidative phosphorylation, potentially reducing cancer cell growth.
6. Vitamin C: High-dose intravenous vitamin C acts as a pro-oxidant in cancer cells, generating hydrogen peroxide and inducing cell death.
7. Hydroxycitrate: This compound inhibits ATP citrate lyase, an enzyme involved in lipid synthesis, which is crucial for cancer cell growth.
8. Artemisinin: Derived from the sweet wormwood plant, artemisinin induces apoptosis in cancer cells by generating reactive oxygen species.
These therapies, combined with lifestyle interventions, aim to disrupt cancer's energy sources and stem cells, offering a promising new approach to cancer treatment.
Types of Cancer Treated
1. Lung Cancer: Some older men with recurrent lung cancer have turned to this combination after conventional treatments failed.
2. Prostate Cancer: Similar to lung cancer, patients with recurrent prostate cancer have explored this protocol.
3. Breast Cancer: Younger patients with aggressive forms of breast cancer, often referred to as "turbo cancers," have also used this combination.
4. Colorectal Cancer: This protocol has been considered by patients with early-onset colorectal cancer.
5. Lymphoma: Some patients with lymphoma have tried this combination as part of their treatment.
6. Pancreatic Cancer: Mebendazole has shown potential in slowing pancreatic cancer progression and preventing tumor recurrence.
Reported Successes
• Leukemia: There have been reports of patients with leukemia achieving remission using protocols that include fenbendazole and ivermectin.
• Pancreatic Cancer: A study from Johns Hopkins indicated that mebendazole might help slow the progression of pancreatic cancer and increase the durability of response to standard chemotherapy.
• General Cancer Care: A recent peer-reviewed study highlighted the potential of combining ivermectin, fenbendazole, and natural compounds like Vitamin E, curcumin, and CBD to enhance immune system function, support cellular repair, and limit cancer cell proliferation.
These findings suggest that the combination of these drugs, along with other supportive therapies, may offer a promising approach to cancer treatment. However, it's important to note that these treatments are often considered off-label and may not have undergone extensive clinical trials yet.
#CancerResearch #CancerTreatment #OrthomolecularMedicine #Ivermectin #Mebendazole #Fenbendazole #StemCells #OxPhos #CancerTherapy #CancerCare #CancerAwareness #InnovativeCancerCare #CancerProtocols #MitochondrialHealth #HybridProtocol #ChronicDiseaseManagement #CancerHealing #HealthInnovation #OncologyResearch #AlternativeCancerTreatment